BioSpace News Archive

McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2021 financial results after market close on Thursday, May 6, 2021. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, April 29, 2021. Management will hold a conference call to review the company’s first quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day.

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus ® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

CytRx Corporation (OTCQB: CYTR) (“CytRx”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) announced that its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (“IBM”) did not meet its primary and secondary endpoints.

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted stock units to be distributed to one new employee with a grant date of April 1, 2021.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to Erik Sims in connection with his employment with the Company as Controller of the Company effective on April 1, 2021.

StageZero Life Sciences, Ltd. ( reports financial results for the three and twelve months ended December 31, 2020, and provides an update on its business progress.

the U.S. Food and Drug Administration announced two revisions regarding the number of doses per vial available for the Moderna COVID-19 Vaccine.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that based on submitted stability data, the U.S. Food and Drug Administration has authorized the Moderna COVID-19 Vaccine to be kept at room temperature conditions once removed from the refrigerator for administration for 24 hours, an increase from the previous 12 hours.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production.